Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Research links low-energy falls to triage undertreatment in female brain injuries

15

Jun 2026

Research links low-energy falls to triage undertreatment in female brain injuries

Female patients with traumatic brain injury (TBI) are 26% less likely to be admitted to a specialized trauma center than males, according to a study on data from Ontario published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.251721. This difference persisted even after the researchers accounted for factors such as age, severity of injury, other health conditions, and socioeconomic circumstances.

Researchers map rare DHDDS disease mechanism using lab-grown mini brains

15

Jun 2026

Researchers map rare DHDDS disease mechanism using lab-grown mini brains

Variants in the DHDDS gene cause a severe neurodegenerative condition, characterized by tremors, seizures, coordination and learning difficulties, usually manifesting in early childhood. This Parkinson's-like condition is extremely rare, and until recently, parents were told that there was nothing that could be done to slow down its progression.

AI could help food systems detect pathogens, fraud, and contamination faster

15

Jun 2026

AI could help food systems detect pathogens, fraud, and contamination faster

A systematic review of 161 peer-reviewed publications found that AI research in food safety has expanded rapidly, rising from one study in 2012 to 46 in 2023. The review shows that machine learning and deep learning are being studied for pathogen detection, chemical contamination prediction, food fraud screening, outbreak surveillance, and regulatory decision-making, but data gaps, class imbalance, privacy limits, and model interpretability remain major barriers.

Digital brain twin recreates brain activity in a toddler with autism

14

Jun 2026

Digital brain twin recreates brain activity in a toddler with autism

Researchers developed FEDE, a high-fidelity digital brain twin pipeline that combines MRI-derived anatomy with biophysical modeling to reconstruct brain structure and simulate EEG activity. In a single toddler with autism spectrum disorder, the model closely reproduced recorded brain activity and suggested possible patient-specific alterations in neural noise and excitatory-inhibitory balance.

Glucosamine may worsen Alzheimer’s by fueling abnormal brain glycosylation

14

Jun 2026

Glucosamine may worsen Alzheimer’s by fueling abnormal brain glycosylation

A Nature Metabolism study identifies brain hyperglycosylation as a metabolic driver of Alzheimer’s disease, with increased N-glycan biosynthesis seen in human AD tissue and mouse models. Reducing glycosylation improved memory in AD mice, while glucosamine worsened memory deficits in 5xFAD mice and was associated with poorer outcomes in dementia patients.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.